The Psychiatrist: Clinical and Therapeutic Journal

Mini Review Open Access

Nanomedicine and Cerebral Palsy: New Perspectives and Causes for Cerebral Palsy

Ulrich Kutschera*

Environmental Department, Pario Psychology & Environmental Sciences, Dartmouth, Japan

Abstract

It is a chronic childhood disorder with numerous possible causes. Injury to the developing brain during pregnancy or shortly after birth can cause the motor, sensory, and cognitive deficits associated with cerebral palsy. Even though the causes of cerebral palsy vary, neuroinflammation plays a critical role in the pathophysiology of brain injury. Cerebral palsy currently has no effective treatment. Nanomedicine provides a new avenue for research and development of treatments for brain injury that causes cerebral palsy. Dendrimers and other nanomaterials allow multiple drugs to be delivered precisely to the cells responsible for neuroinflammation and injury, reducing the number of injury-related pathways. Furthermore, these materials allow for the delivery of agents that promote brain repair and regeneration, reducing injury and facilitating normal growth. The most recent advances in nanotechnology for the treatment of brain injuries, with a focus on cerebral palsy, are discussed. Possible future directions for making clinical translation easier for children and newborns are also discussed.

Introduction

Cerebral palsy (CP), a chronic disability that affects children, has no cure; it imposes significant personal, social, and financial costs. An orthopaedic surgeon named William John Little observed in 1862 that newborns who were subjected to asphyxia or mechanical injury prior to or during childbirth developed rigidity and limb distortion later in life. Little was the first to describe cerebral palsy. Initially, it was thought that CP was simply a movement disorder caused by white matter damage. This is because the most common symptoms in these patients are coordination and movement issues, such as spasticity, rigidity, ataxia, and muscle weakness [1]. Subsequent research, on the other hand, has shown that, in addition to white matter injury, grey matter abnormalities in the structures of the cortex and subcortical contribute to these patients' developmental delays, cognitive disturbances, and psychomotor abnormalities. "Group of permanent disorders of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing foetus or the infant brain," is a more comprehensive definition of CP that now includes these symptoms.

The efficacy of hypnosin as a treatment for cerebral palsy was studied in 19 patients. Four patients improved significantly; however, the overall results were unimpressive [2].

The following four patients were successful:

1) enhanced writing and speaking abilities

2) improved walking ability

3) an improvement in hyperesthetic foot pain

4) A shift in personality from obvious shyness to a more sociable demeanour.

Trancopal, Librium, and Nembutal, all in low doses, did not aid in the induction of hypnosis. Along with the hypnotic state, meaningful interpersonal relationships formed during therapy are likely to have played a significant role in the patient's improvement. Given the few cases where hypnosis has a clearly beneficial effect, more research and evaluation of this approach to cerebral palsy therapy is required.

Factors Predisposing to Cerebral Palsy A few risk factors for CP have been identified, including very low birth weight, prematurity, intraventricular haemorrhage, multiple pregnancies, chorioamnionitis, hypoxia, neonatal encephalopathy, foetal infections, and genetic factors.

The primary pathophysiological mechanisms that cause cerebral palsy are broadly classified as follows:

1) Hypoxia and ischemia, which cause a cascade of excito-oxidative events in the brain;

2) Intrauterine infections/inflammation, which cause the foetal inflammatory response syndrome and neuroinflammation

3) Congenital or genetic causes. These mechanisms can sometimes cooperate. Neuroinflammation and periventricular leukomalacia (PVL) are two common pathological substrates for CP, which can be caused by a variety of factors.

Immune cells in the brain, such as infiltrating macrophages and microglia, are responsible for central nervous system inflammation (CNS). Activated microglia and astrocytes have been linked to a variety of neurodegenerative conditions in both children and adults. Periventricular leukomalacia is the pathophysiological substrate of CP in humans, characterised by diffuse microglial and astrocyte activation in the immature white matter and focal necrosis around the ventricles [3].

Microglia and astrocytes, the two most important glial cells in the brain, play critical roles in central nervous system repair and injury (CNS). Microglia are the more important of the two during brain development and remodelling. Microglia appear along the white matter tract in the late second trimester of human development and

***Corresponding author:** Ulrich Kutschera, Environmental Department, Pario Psychology & Environmental Sciences, Dartmouth, Japan, E-mail: KutscheraU@gmail.com

Received: 01-Feb-2023, Manuscript No tpctj-23-90605; **Editor assigned:** 03-Feb-2023, PreQC No. tpctj-23-90605 (PQ); **Reviewed:** 17-Feb-2023, QC No tpctj-23-90605; **Revised:** 23-Feb-2023, Manuscript No. tpctj-23-90605 (R); **Published:** 2-Mar-2023, DOI: 10.4172/tpctj.1000175

Citation: Kutschera U (2023) Nanomedicine and Cerebral Palsy: New Perspectives and Causes for Cerebral Palsy. Psych Clin Ther J 5: 175.

play a supporting role in myelinogenesis and axonogenesis . Although microglia's primary function during development is to act as a support system, their presence can make the developing brain more vulnerable to various brain injuries.

The Dohsa method for children with cerebral palsy

The Dohsa method is an effective therapy for children with autism that was originally developed in Japan for children with cerebral palsy. This article discusses the theoretical foundation, therapeutic approaches, and the efficacy of the method. Finally, the need to integrate this approach with other approaches to therapy is raised.

Nanoparticles for the treatment of brain injuries Despite advances in CNS therapies and increased understanding of disease aetiology and progression, CNS disease treatment remains a significant challenge. There aren't many studies that show how important early detection, prognosis, and treatment success are. Nanotechnology-based approaches are providing potential platforms for CNS therapy. The physicochemical properties of nanoparticles can be altered to avoid BBB and improve their penetration and diffusion through the brain parenchyma, allowing for the controlled and ongoing release of a therapeutic. Preclinical research indicates that these strategies have the potential to treat a wide range of CNS conditions, including cancer, neuroinflammation, and neurodegeneration.

Dendrimers stand out among the various nanoparticle platforms as promising drug delivery vehicles due to their small size, adaptable end groups, and favourable biosafety profile. Eyesight changes Eye changes are a common cause of visual impairment in cerebral palsy (CP) [4]. The purpose of this research was to discover a link between the type and severity of cerebral palsy and the frequency, type, and characteristics of ophthalmic abnormalities in cerebral palsy patients.

Risk factors for cerebral palsy during pregnancy include: An event that damages the brain is more likely to occur in infants than in older children.

• Premature or underweight birth: Premature or underweight infants are more likely to develop cerebral palsy.

• Failure to obtain certain vaccines. Vaccinations for children can help prevent brain infections that can lead to cerebral palsy.

• Accidents Failure to take certain safety precautions for infants or the absence of adult supervision can result in cerebral palsy.

• Migraines. Infant seizures increase the likelihood of developing cerebral palsy later in life.

• A labour and delivery process that is difficult. Infants with heart or breathing problems are more likely to have cerebral palsy during labour and delivery and immediately after birth.

• Infertility treatments. Infants born from pregnancies unrelated to infertility treatments are more likely to have cerebral palsy than infants born from pregnancies unrelated to infertility treatments. A significant portion of this increased risk may be attributed to the fact that infertility treatments are more likely to result in multiple pregnancies and preterm births [4].

• The fetus and mother's blood factors do not match. Rh positive people have a particular protein that is found on red blood cells and is abbreviated as Rh. Rh-negative individuals are those devoid of the protein. The mother's immune system may attack the fetus's blood cells, including blood cells in the brain, if the mother's Rh factor differs from the fetus's.

Congenital laryngeal palsy is another name for congenital vocal cord paralysis. It could affect either one or both vocal cords (unilaterally) (bilaterally) [5-10]. There is frequently no known cause of idiopathic bilateral vocal cord paralysis. In some cases, nerve or muscle immaturity (neuromuscular) or central nervous system damage (such as the Arnold-Chiari malformation, cerebral palsy, hydrocephalus, myelomeningocele, spina bifida, hypoxia (lack of oxygen in the blood), or bleeding) can result in paralysis. A birth trauma that causes excessive neck tension can result in transient bilateral vocal cord paralysis that can last six to nine months. Most of the unilateral paralysis is idiopathic, but it can also be caused by vagus nerve problems or repeated laryngeal nerve trauma. Flexible endoscopy can be used to diagnose the condition.

Conclusion

A thorough evaluation of nanoparticles in vivo is necessary to address issues of biosafety and toxicity as the therapeutic field of nanotechnology advances and cationic amine terminal G4 dendrimers were found to be toxic in developing zebra fish embryos, respectively. Teratogenic effects on the embryo were observed when multiwalled carbon nanotubes were injected into pregnant mice. It is essential to determine the dose, type of nanoparticle, and route of administration to maintain a balance between maximum therapeutic efficacy and reduced toxicity in the developing brain. We have demonstrated that administering 550 mg/kg of G4OH PAMAM dendrimer to newborn rabbits, which is ten times the dose used in the efficacy studies, did not result in any toxic effects. It is possible that the dendrimer surface's neutral -OH groups are to blame for these animals' improved safety profile. However, to establish the biosafety profile of the hydroxyl-terminated dendrimers for prenatal and postnatal treatment, additional research with larger animals would be necessary.

References

1. Akgor U, Erdem F, Burcu S, Canan U, Murat C, et al. (2021) Anxiety, depression and concerns of pregnant women during the COVID-19 pandemic. Arch Gynecol Obstet 304: 125-130.
2. Areej EJ, Jamie MJ, Ashley MN, Lara T, Joseph AG, et al. (2020) Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. Cancer 126: 1758-1765.
3. Loretta H, Alexandra W, Steven H, Sarah AO, Mark AL, et al. (2021) Clinical psychology PhD students' admission experiences: Implications for recruiting racial/ethnic minority and LGBTQ students. J Clin Psychol 77: 105-120.
4. Eunice W, Robert H, Caroline L, Sally B, Matthias Z (2021) The growing gap between demand and availability of clinical psychology in Paediatric Gastroenterology: a retrospective analysis of clinical routine care. Eur J Pediatr 180: 1307-1312.
5. Franziska K, Destina SA, Mara JO, Florian W (2018) Standardized Patients in Clinical Psychology and Psychotherapy: a Scoping Review of Barriers and Facilitators for Implementation. Acad Psychiatry 42: 773-781.
6. Konstantakopoulos G (2019) Insight across mental disorders: A multifaceted metacognitive phenomenon. Psychiatriki 30: 13-16.
7. Paul T (2012) Severe personality disorder in the secure estate: continuity and change. Med Sci Law 52: 125-127.
8. Gillian AMC, Thomas AW (2020) Discriminant validity of the alternative model of personality disorder. Psychol Assess 32: 1158-1171.
9. Ashley AH, Michael RF, Elizabeth MA, Mary KL, Malek M, et al. (2014) The structure of borderline personality disorder symptoms: a multi-method, multi-sample examination. Personal Disord 5: 380-389.
10. Gabrielle B, Steve W, Katherine W Z (2021) A dis-ordered personality? It's time to reframe borderline personality disorder. J Psychiatr Ment Health Nurs 28: 469-475.